<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 109 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page108.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=109">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 109 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 109</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=109"><img src="../thumb/109.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>78 / 2020-04                                                      Musculo-Skeletal Agents -  4.5 / 4.6
   Drug interactions: Potent.sedat.effs.of other CNS depress.& alcoh.,   only, safety & effic. not studied in elderly, concom meds.metabolis.by   at incr. risk for skin Ca/non-melanoma skin cancer, bld dyscras.hist.,
   TCA’s potent.eff., incr.fall in BP with antihypertens., sev.aggravat.of   CYP2C8/ CYP1A2, INR follow-up & monitor.with concom. warfarin,   impact of long term treatm.on autoimmune dis. unknown., concur.
   hyperkinet. sympts.with Li.  lact.intol., pts.und.18 yrs.as safety & effic.not stud.  live vaccin.should not be giv., paed.pts.to be uptodate with loc.immu-
                                Interactions: Poss.decr.expos.with concom. rifampicin/ carbamaz-  nisat.guidelines bef. init.ther, caref.evaluat.in pre-exist./recent onset
                                epine, phenobarbitone/ phenytoin/ St John’s Wort, poss.incr.C max &   of CNS demyelinat.dis/those at incr.risk.thereof, CHF,
   4.6    Others                AUC of repaglinide/ paclitaxel/pioglitazone, poss.decr. C max & AUC   do not add other meds to sol., safety in pregn. & lactat. not est.,
                                of duloxetin/theophylline/tizanidine/ caffeine, incr. C max and AUC of
                                                              crosses placenta & excret.in human milk, not stud.in childr.&lt;2yrs.
   ORENCIA (MDR Listing)        concom. ethinylestrad./ levonorgestrel.  Interactions: Poss.concom.anti-diab.meds.dos. reduct., concom.
   RHEUMALEF (MDR Listing)      ENBREL, Pfizer [P/S]          anakinra assoc.with incr.risk of ser.infect. & neutropen., incr. ser.
                                                              advers.events with concom.abatacept, mean WBC.decr.with
   ARAVA, Sanofi-Aventis [P/S]  Etanercept                    sulfasalazine.
   Leflunomide                  Indications: Alone/in combinat.with methotrex. to reduc.S&S &
   Indications: Act.rheumat.arthrit.in adults as a dis. modify.antirheu-  inhib.struct.damage progress.of act.RA in adults where respons.to   LUNAR, Cipla Medpro [P/S]
   mat.drug (DMARD).& improv. physic.funct.  one/more dis. modify.antirheumat.meds.inadeq., sev.act. progress.   Leflunomide
   (S4) TABS, 33/3.1/0290, 0291  RA in adults not prev.treat.with methotrex., polyartic.-course juven.  Indications: Act.rheumat.arthrit.in adults as a dis. modify.antirheu-
   898171-008: 10 mg, 30, R918,41  idiopath. arthrit. in childr. & adolesc.from 2 yrs.where respons. to one   mat.drug (DMARD).& to improv. physic. funct.
                                                              (S4) TABS, 45/3.1/0812
                                more more dis modify.antirheumat. inadeq., act.polyartic.-course ju-
   898175-005: 20 mg, 30, R938,60
   Dosage: Init.load.dos: 100 mg once dly.x3 days. Recomm.maint: 10-  ven.idiopath. arthrit. & extend.oligoarthrit.in childr.& adolesc. from   721806-001, 20 mg, 30’s, R824,44
                                2 yrs.where intol./inadeq.methotrex.respons., psoriatic arthrit.from
                                                              Dosage: Treatm.only by drs.exper.in rheumatoid dis.
   20 mg once dly. Therap.eff. usual aft.4-6 wks.with poss.improvem.
   up to 4-6 mnths.             12 yrs.where methotrex. respons. inadeq./intol., enthesitis-relat.   Load.dose: 100 mg once dly.x3 days. Recomm.maint.: 10-20 mg
                                                              once dly. Therap.eff. usual seen aft.4-6 wks.with poss.improvem.
   Contraindications: Imp.liv.funct., sev. immunodefic. states, signific.  arthrit. from 12 yrs.where respons.inadeq./intol.to convent. ther., to
   imp.bone marr.funct. /signif.anaem., leukopen/neutropen/ thrombo-  reduc.S&S & inhib.struct. damage progress.of act.arthrit.in psoriat.  up to 4-6 mnths.
   cytopen. from causes other than rhemat. arthrit., ser.infects., mod.-  arthrit.& may be combin.with methotrex.in those not respond. adeq.  Contraindications: Imp.liv.funct., sev. immunodefic. states, signific.
   sev.ren.insuffic., sev. hypoproteinaem., pregn., women of childbear.   to methotrex.alone, S&S reduct.in ankylos. spondylit., adults with sev.  imp.bone marr.funct. /signif. anaem., leukopen/neutropen/ thrombo-
   potent., lactat., pts.und.18 yrs.as safety & effic. not studied, concom.  non-radiograph. axial spondyloarthrit.with inflammat. signs & evid   cytopen. from causes other than rhemat. arthrit., ser.infects., mod.-
                                                              sev.ren.insuffic., sev. hypoproteinaem., pregn., women of childbear.
                                but not respons./intol.to convent. ther., chron. mod.to sev.plaque
   DMARD not recomm., concom. cholestyramine.
   Side effects: GI disturbs., liv.paramet.elev., hepatis., jaund., choles-  psorias.in adult system.ther./photother candidat., childr.& adolesc.   potent (unless adeq.contracept.), lactat., pts.und. 18 yrs. as safety &
                                                              effic.not studied, concom. DMARD not recomm., concom.cholesty-
                                from 6 yrs.with chron.sev.plaque psorias.inadeq. controll,./intol.to
   tas., pancreatit., sev.liv.inj., hepat.fail., ac.hepat. necros., incr.BP, bld.
   dyscras., CNS effs., allerg./ anaphylact.reacts.incl.Stev. Johns.syndr./  other system.ther./photother.  ramine., lact. intol.
                                                              Side effects: Bronchit., RTI/UTI, sev.infect.& sepsis poss.fatal, incr.
   erythema multiforme & tox.epiderm. necrolys., vasculit., sev.infects.&   (S4) INJ, 34/3.1/0330, 34/34/0331. 25 mg.
   seps., interstit. lung dis.,weight loss, asthen., hypokalaem., mild hy-  702509-001: 4xsngl.dos.vial.& syr., R4 617,12  lymphoproliferat.disord.risk, leukopen., bld.dyscras., allerg./anaphy-
                                                              lact.reacts., hypokalaem., hypouricaem., anx., paraesthes., headache,
   perlipidaem., decr.uric acid levs., incr malign.risk partic.lymphopro-  (S4) PRE-FILLED PS INJ, 41/3.1/0762, 0763.
   liferat.disords.with some immunosuppress. drugs  715037-001: 25 mg, 4xpre-filled.syr., R4 617,17  dizzin., taste disturb., periph. neuropathy, conjunctivit., incr.BP., chest
                                                              pain, palpitat., tachycard., interstit.lung dis., dyspn., pharyngit., rhinit.,
   Special precautions: Teratogen.in rats & rabbits, male pts.to be   715051-002: 50 mg, 4xpre-filled.syr., R9 234,34  sinusit., GI disords.incl pancreatit., hepatotox., elev.liv.param., hepat.
                                Dosage: Concom.methotrex./glucocortic./ salicylates / NSAID’s or
   aware of poss.male-med. fetal toxic., without drug eliminat.proced.
   it may take up to 2 yrs.to reach prim.metabol.lev.of &lt;0,02 mg/L, instit.  analges.may be cont.dur. ther. Admin.as SC inj.alternat.sites. Do not   fail, ac.hepat.necros., hepatit., jaund., cholestas., eczema, dry skin,
                                                              alopec., skin rash, prurit., tox. epiderm.necrolys., Stev.-Johns.syndr.,
   washout as describ.in lit.for any women wish.to fall pregn./men wish.  inj.into tender/bruis./red or hard areas.
   to father childr./ when switch.to another DMARD aft. treatm./ if sev.  Adults:  urticar., vasculit., joint disords., synovit., tenosynovit., ren. fail., weigh
                                                              loss, asthen., back pain, malaise, fev.
   haematolog./sev.skin reacts./sev. uncontrol.infects.occur, contracept.  Rheumat.arthrit: Adults.18 yrs.& old: Optim. therapeut. respons:
   other than OC’s recomm.dur.washout,reliab.contracept., for use by   50 mg/wk. Admin.once wkly as 2x25 mg SC inj.at approx.same time   Warnings and special precautions: Teratogen. in rats & rabbits,
                                                              male pts.to be aware of poss. male-mediat.foet.toxic, instit.washout
   exper. physic.only, check ALT(SGPT) bef.init.ther.& at mnthly interv.x   OR 25 mg SC 2x/wk 3-4 days apart OR 50 mg PS pre-fill.syr.SC 1x/wk.
   1  6 mnths.& every 6-8 wks. thereaft., discont.if ALT(SGPT) elev.of   Psoriat.arthrit., ankylos.spondylit.& non-radiograph. axial   as describ. in lit.for any women wish.to fall pregn./men wish. to fa-
   st
                                                              ther childr./when switch.to another DMARD aft. treatm./if sev.hae-
   &gt;3 fold the upper limit of norm.persist., monit.BP bef.init. treatm. &   spondylarthrit: Recomm. dos: 50 mg/wk.admin.as 25 mg SC 2x/  matolog./sev.skin reacts./ sev. uncontrol.infects.occur, contracept.
                                wk 3-4 days apart.
   periodic.thereaft., perform complete bld. cell count bef.init.treatm.&   other than OC’s recomm.dur.washout, reliab. contracept.to be guar-
          st
   thereaft.mnthly x1  6 mnths & then every 6-8 wks., use with antimalar.  Plaque psorias: 50 mg/wk. Admin.as 50 mg by pre-fill.syr.1x/wk.OR   ant.dur.treatm., check ALT(SGPT) bef.init. ther.& at mnthly interv.x 1   st
   in rhemat. dis./ intramusc./oral gold/D-penicillam./ azathiopr.& other   25 mg 2x/wk.3-4 days apart. High. respons. may be achiev.with init.  6 mnths.& every 6-8 wks. thereaft., discont.if ALT(SGPT) elev.of 2-3
   immunosuppress.agents not studied, unknown treatm.risk partic.in   treatm.upto 12 wks. with 50 mg 2x/wk. Treatm.to be indiv.either as   fold ULN persist./if confirm.ALT elevat.&gt;3-fold ULN present & admin
   long term treatm. with combin.ther., combinat.with another DMARD   intermitt/contin.treatm. Discont.if no respons.aft.12 wks. Subseq.to   cholestyram.or activat.charc.to rapid.low.lev.of act.metabolite, monit.
   not advis.poss.lead.to addit./synergist. tox., poss.incr.S/E with recent   init.cycle intermitt. treatm.is dos of 50 mg once wkly.or 25 mg 2x/wkly.  BP bef.init. treatm. & periodic.thereaft., perform complete bld. cell
   hepatotox./ haematotox. drug treatm., avoid alcohol due to potent.   Childr. Dos.for pts.weigh.&lt;62,5 kg bas.on mg/kg basis using   count bef.init.treatm.& thereaft.mnthly x1  6 mnths & then every 6-8
                                                                               st
   addit. hepatotox.effs., incr.risk of haematolog. disords.in pts.with pre-  powd.& solv.for inj. & for those over 62,5 kg use fix.dos.pre-fill.  wks., use with antimalar.in rheumat.dis./ intramusc.or oral gold/D-
   exist.bld. dyscras./ imp.bone marr.funct./pts.at risk of bone marrow   syringe/prefill.pen
   suppress., discont.in case of sev. haematolog. reacts.incl. pancyto-  Juven.idiopath.arthrit: ≥2 to &lt;18 yrs: 0,4 mg/kg upto max.25 mg/   penicillam./ azathiopr. & other immunosuppress.agents not studied,
                                                              risk assoc.with combin.ther. & partic.in long term treatm.unknown,
   pen./ulcerat. stomatit./sev.uncontrol.infects., incr.suscept.to infects.   dos.admin.SC 2x/wk.with 3-4 day interv.betw.dos.OR 0,8 mg/kg up   combinat.with another DMARD not advis.& could lead.to addit./
   due to poss. immunosuppress., meds.other than NSAID’s metabol.  to max.50 mg once wkly. Concom.glucocortic./NSAID’s or analges.   synergist. tox., poss.incr.S/E with recent hepatotox./ haematotox./
   by CYP2C9, concom. rifampicin, concom.live vaccinat.not recomm.,   may be cont.dur.ther.  immunosuppress.drug treatm., avoid alcohol due to potent.addit.
   early & aggress. treatm.of suspect.infects., liv.funct. impairm., pts to   Paed.plaq.psorias.: ≥6 to &lt;18 yrs: 0,8 mg/kg(up to max.50 mg/  hepatotox. effs., incr.risk of haematolog.disords.in pts.with pre-exist.
   report pulm.sympts.e.g.cough & dyspn. which should be investigat.  dos.) once wkly for up to 24 wks. Discont. if no respons.aft.12 wks.   bld.dyscras./imp.bone marr. funct./ pts.at risk of bone marrow sup-
   to excl.interstit. lung dis., monit.tuberculin react.pts.for tuberculos.   If re-treatm. indicat. follow above guid.on treatm.durat. Dos: 0,8 mg/  press., perform freq.haematolog.monit.in pts.at risk of haematologic.
   reactivat. risk, ren.impairm.  kg(up to max.50 mg/dos.) once wkly  disords., discont.in case of sev. haematolog.reacts.incl.pancytopen.,
   Drug interactions: Incr.prothromb.time with warfarin., cholesty-  Contraindications: Sepsis or risk thereof, ser. act.infects.incl.  discont.in case of ulcerat.stomatit./sev.skin or mucos. reacts. & avoid
   ramine & act.charcoal decr. plasma prim.metabol.conc.  chron/local.infects.  re-expos., discontin.in case of sev. uncontrol. infects., incr.suscept.
                                Side effects: Inj.site reacts.incl.bleed.& bruis., ser. & fatal infects.
   AUBAGIO, Sanofi-Aventis [P/S]  incl.TB & sepsis, opportunist. infects.incl.invas.fung./parasit. incl.  to infects.due to poss. immunosuppress., meds.other than NSAID’s
   Teriflunomide                protozoal)/ bact. & atypic.mycobact.infects., malign.affect. var.sites   metabol.by CYP2C9 as enzyme activity inhibit., concom. live vaccin.
   Indications: Relaps.forms of multiple scleros.in adults to reduce   report.in post market.period, incr. developm. of new posit.antinu-  not recomm., early & aggress. treatm.of suspect.infects., liv.funct.im-
   freq.of relaps.& to delay accumulat. of physic.disabil.  clear antibod./new pos.anti-double-stranded DNA antibod.& new   pairm., pts. to report pulm.sympts. e.g. cough & dyspn.which should
   (S4) TABS, 47/32.16/0859     anticardiolipin antibod., addit.autoantibod. developm. in conjunct.  be investig.to excl.interstit.lung dis., monit. tuberculin react.pts.as
   721520-001: 14 mg, 28, R7 636,00  with lupus-like syndr/ rashes.  tuberculos.reactivat.risk, ren. impairm., consid.discont.with periph.
   Dosage: Admin.supervis.by exper.practit. Recomm.dos: 14 mg   V.common: Infects.incl.URT/UTI/bronchit.& skin, inj.site reacts.   neuropathy, INR monit.with co-admin.warfar.
   once dly.                    Common: Allerg.reacts., autoantibody format., prurit., fev. Un-  Drug interactions: Cholestyramine & act. charcoal decr.plasma
   Contraindications: Sev.hepat.impairm., co-admin. with lefluno-  common: Ser. infects.incl.pneumon./cellulit./sept.arthrit./ sepsis &   prim.metabol.conc., incr. peak lev.of prim.metabol.with concom.
   mide, pregn./wom.of child bear. potent.not on reliable contracept.  parasit., non-melanoma skin Ca, thrombocytopen., system.vasculit.  rifampicin.
   Side effects: Infects.& infestats.incl.influenza/ URTI / UTI, incr.ALT,   incl. ANCA posit. vasculit., uveit., sclerit., interstit.lung dis.incl. pulm.  NIVAQUINE, Sanofi-Aventis (Pty) Ltd
   GI disturbs., alopec., neutropen., season.allerg., anx., CNS effs.incl.   fibros.& pneumon., rash, urticar., angoed., psorias. of new onset/exac-  See Section 18.11
   paraesthes., hypertens., rash, acne, musculoskelet. pain, myalg., pol-  erbat., psoriasiform rash. Rare: TB, opportunist.infects., melanoma,
   lakiur., menorrhag., pain, post-traumat. pain, sev.liv.inj., hepat.fail., liv.  anaem., leucopen., neutropen., panctopen., ser. allerg./anaphylact.  ORENCIA 125 mg SC INJ, Equity &
   paramet. elev., hepatis., jaund., incr.gamma-glutamyltransfer. / aspar-  reacts., seiz., CNS demyelinat. events.incl.MS & local.demyelinat.  Abatacept
   tate aminotransfer, decr. weight/ neutroph.count/white bld.cell count.  condit., CHF, elev. liv.enzym., autoimmune.hepatit., cutan. vasculit.  Indications: Alone/in combinat.with dis.modify. anti-rheumat.
   Warnings and special precautions: Teratogen. in animals, obt.  incl.Stev.John.syndr., erythema multiforme, subac.cutan.& discoid   meds.(DMARDs) other than tumor necros.fact.block.agents(TNF) to
   transamin.& bilirub.levs.within 6 mnths. bef.init.& monit.ALT levs.at   lupus erythematos, lupus like syndr., V.rare: Aplast. anaem., tox.  reduc.S&S/induc. major clinic.respon/inhib.struct.damage progress.
   least mnthly. for 6 mnths., discont.& start accelerat.eliminat. proced. if   epiderm. necrolys.   & improv.phys.funct. in adults with act.RA.
   drug induc.liv.inj.suspect., discont.if ALT elev. of &gt;3 fold the upper limit   Warnings and special precautions: No clinic. exper.beyond   (S4) SOL FOR SC INJ, 47/3.1/0467. 125 mg
   of norm.persist., pre-exist.liv.dis., monit.BP bef.init.treatm.& periodic.   1 yr., underly.dis.predispos.pts.to infect./hist.of recurr.infects./high   722109-001: 4xprefill.syr., R8 184,90
   thereaft., pts.with active ac./chron. infects. should not start treatm.,   risk of develop. ser.infect., maj.surg, monit.pts.on ther.develop. new   Dosage: Not intend.for IV infus. Rotate inj.sites.
   susp.treatm.if pts. devel.ser.infect.& reassess benef.vs risks prior to   infect., discont.ther.if ser.infect./sepsis/bld. dyscras develops, eval.  125 mg SC admin.wkly.regardless of weight/with/-out an IV load.dos.
   re-initiat., perform bld.cell count bef.init.treatm.& periodic.thereaft.,   pts.for infects./act.or lat.TB & hepatit.B or C bef./dur.& aft.treatm.,   If init.ther.with an IV load.dos.admin sngl.IV infus. follow.by 1  125 mg
                                                                                      st
   concom.live vaccinat.not recomm., co-admin.with antineoplast./ im-  admin. prophylact. latent TB ther.bef.init.ther., recurr. infect. hist./  SC inj.& then SC inj.wkly thereaft.
   munosuppress. ther.used for treatm.of MS not eval., long term safety   condits.predispos.to infect., rheumat. arthrit.pts.at incr.risk of TB in-  When switch.from IV ther admin.1  SC dos.instead of next sched.IV dos.
                                                                           st
   of other concom.immune modulat.ther.not est., elimin.from plasma   fect., reactivat.of hepatit.B vir.in chron.carriers report., hepatit.B vir.  Contraindications: Compon.hypersens., act./ dorm. untreat.TB.,
   is slow, use accelerat.eliminat.proced.with cholestyramine/ charcoal   carriers., worsen.of hepatit.C, concom.anakinra assoc.with incr.risk   pregn. & lactat.
   as describ.in lit.if rapid. decr.in plasma conc.reqd., fem.pts.to contin.   of ser.infect. & neutropen., incr. ser.advers.events with concom.abata-  Side effects: Headache, naus., U&LRTI, UTI, H.simplex, rhinit., tooth
   contracept. unt.plasma conc. ≤ 0.02 µg/ml, instit. washout as describ.  cept, not recomm.in Wegener’s granulomatous, mod.to sev. alcohol.  infect., infect.skin ulc., onychomycos., pelvic inflamm.dis., basal cell
   in lit.for any women wish.to fall pregn., without drug eliminat.proced.  hepatit., latex hypersens., discont. immed. if ser.allerg./anaphylact.  Ca, bld.dyscras., depress., anx., dizzin., paraesthes., conjunctivit., re-
   it may take 6-24 mnth.to reach plasma conc. &lt;0,02 µg /L, male pts.  react.occurs, risk of developm. of lymphomas/other haematopoiet/   duc.vis. acuity, vertigo, tachycard., bradycard., palpitat., hyper-/hy-
   to be aware of poss.male-med.fetal toxic., for use by exper.physic.  solid malign.cannot be excl., period.skin examinat. recomm.for pts.  potens., flush., cough, abdom.pain, diarrh., dyspeps., gastrit., mouth</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page108.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page104.html">104</a>&nbsp;&nbsp;&nbsp;<a href="page105.html">105</a>&nbsp;&nbsp;&nbsp;<a href="page106.html">106</a>&nbsp;&nbsp;&nbsp;<a href="page107.html">107</a>&nbsp;&nbsp;&nbsp;<a href="page108.html">108</a>&nbsp;&nbsp;&nbsp;<a href="page109.html">109</a>&nbsp;&nbsp;&nbsp;<a href="page110.html">110</a>&nbsp;&nbsp;&nbsp;<a href="page111.html">111</a>&nbsp;&nbsp;&nbsp;<a href="page112.html">112</a>&nbsp;&nbsp;&nbsp;<a href="page113.html">113</a>&nbsp;&nbsp;&nbsp;<a href="page114.html">114</a>
             </td>
             <td width="35%"><a href="page110.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page110.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
